"This decision by Cigna/Evernorth is a significant step forward for adolescent mental healthcare and reflects the momentum we have built with payors over the past year since NeuroStar first received the FDA clearance for adolescents," said Keith J. Sullivan, President and CEO of Neuronetics. "We are grateful that millions more families will now have easier access to NeuroStar TMS as a proven, non-drug treatment for major depression and can get the care they deserve." The expansion is effective immediately, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation or or ...

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company's press release on March 4, 2025 initially issuing the Company's fourth quarter and full year 2024 financial results (the "Initial Release") and in connection with finalizing the audited financial statements for the fiscal year ending ...

Core Viewpoint - Neuronetics (STIM) shares have increased by 16.1% recently, closing at $5.06, with a potential upside of 35% based on Wall Street analysts' mean price target of $6.83 [1] Price Targets - The average price target consists of three estimates ranging from a low of $5.50 to a high of $8, with a standard deviation of $1.26, indicating variability among analysts [2] - The lowest estimate suggests an 8.7% increase, while the highest indicates a 58.1% upside [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [2][7] Analyst Sentiment - Analysts show increasing optimism about STIM's earnings, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [4][9] - The Zacks Consensus Estimate for the current year has risen by 58.8% in the past month, with two estimates increasing and no negative revisions [10] Zacks Rank - STIM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] Conclusion on Price Targets - While consensus price targets may not reliably predict the extent of STIM's gains, they can provide a directional guide for potential price movements [12]

Neuronetics, Inc. (NASDAQ:STIM) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Max Kruszeski - William Blair Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics Fourth Quarter 2024 Financial and Operating ...

MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Acquired Greenbrook TMS on De ...

Exhibit 99.1 Neuronetics Provides Business Update and Issues 2025 Guidance MALVERN, PA., January 13, 2025 – Neuronetics, Inc. (NASDAQ: STIM) (the "Company") today announced preliminary fourth quarter and full year 2024 revenue and issued 2025 financial guidance. Preliminary Fourth Quarter and Full Year 2024 Results Neuronetics' preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectively. These results reflect Neuronetics' standalone performance through December 10, 2024 ...

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call wi ...

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company") today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company has also granted to the underwriter ...

Company Overview - Neuronetics, Inc. is a global leader in neuroscience, focusing on mental health treatments, particularly through its NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions [6][7] - The company operates Greenbrook TMS Inc. treatment centers across the United States, providing NeuroStar Therapy for major depressive disorder and other mental health disorders [6] Public Offering Details - Neuronetics has priced its underwritten public offering of 8,000,000 shares of common stock at a price of $2.25 per share, aiming for gross proceeds of approximately $18 million [1][2] - The underwriter has a 30-day option to purchase an additional 1,200,000 shares at the public offering price [2] - The net proceeds from the offering will be used for general corporate purposes, including sales and marketing, research and development, potential acquisitions, and working capital [2] Regulatory and Compliance - A shelf registration statement for the shares was filed with the U.S. Securities and Exchange Commission (SEC) on November 9, 2022, and was declared effective on November 14, 2022 [4] - The offering will be made via a prospectus supplement, with a final prospectus supplement to be filed with the SEC [4] Financial and Market Context - The offering is expected to close on or about February 10, 2025, subject to customary closing conditions [2] - Canaccord Genuity LLC is acting as the sole bookrunner for the offering [3]